drugset / Trial / NCT01644617

A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)

NCT01644617

Phase 2 Completed 124 enrolled ALK-Abelló A/S Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the dose-related effectiveness, the safety and the tolerability of MK-8237, compared to placebo, in the treatment of house dust mite (HDM)-induced allergic rhinitis/rhinoconjunctivitis in adults. The primary hypothesis is that administration of MK-8237, compared to placebo, results in dose-related improvement in the average total nasal symptom score (TNSS) determined during environmental exposure chamber (EEC) challenge.

Timeline

Start
2012-10
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-8237 Unknown 6 unknown Other
Subject MK-8237 Unknown 12 unknown Other